Maki Oncology Clinic: Precision Low-Dose Immunotherapy Specialists
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Maki Oncology Clinic (Nagoya) has pioneered the "Low-Dose Strategy" for modern immunotherapy. Since 2015, the clinic has demonstrated that a fraction of the standard dose of drugs like Opdivo can trigger a potent immune response in many patients.
Personalized Immune Protocols
- Low-Dose Opdivo & Yervoy: Utilizing as little as 20mg of Opdivo to block the PD-1 pathway, significantly reducing the cost and the risk of severe side effects.
- Combination with Cell Therapy: Integrating drug therapy with high-purity NK cell expansion to create a synergistic antitumor effect.
- Proven Clinical Record: The clinic’s findings have been supported by international clinical data, offering a viable path for patients concerned about traditional chemotherapy toxicity.
[Medical Supporter Compliance Statement] Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.